Crescent Biopharma
CBIO
30 hedge funds and large institutions have $83.8M invested in Crescent Biopharma in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more capital invested
Capital invested by funds: $79.3M → $83.8M (+$4.46M)
3% more funds holding
Funds holding: 29 → 30 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.73M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$224K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.2K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$71.8K |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$853K |
| 2 |
Goldman Sachs
New York
|
-$146K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$143K |
| 4 |
SIM
Spark Investment Management
New York
|
-$123K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$51.8K |
CBIO Hedge Fund Activity: Q1 2016 in Review
30 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2016, worth a combined $83.8M — up 5.6% from $79.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CBIO positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.73M. The largest seller was Fidelity Investments, exiting entirely with an estimated $853K sold.
- 30 institutional investors held Crescent Biopharma (CBIO) as of Q1 2016, up from 29 in Q4 2015.
- Funds reported $83.8M of Crescent Biopharma stock for Q1 2016, up 5.6% quarter-over-quarter.
- 4 funds opened new Crescent Biopharma positions in Q1 2016 and 3 closed out, a net change of +1 holder.
- The largest Crescent Biopharma buyer in Q1 2016 was Sphera Funds Management, an estimated $1.73M added.
- The largest Crescent Biopharma seller in Q1 2016 was Fidelity Investments, an estimated $853K sold.
Based on aggregated 13F filings for Q1 2016.